In 2024, Takeda Pharmaceutical completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Takeda Pharmaceutical has also provided a category-level breakdown for 10 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021-2019 |
|---|---|---|---|---|
Total Scope 1 | 273,000a | 279,000b | 277,000b | |
Total Scope 2 | ||||
Market-Based | 28,000a | 33,000b | 169,000b | |
Location-Based | 272,000a | 282,000b | 291,000b | |
Total Scope 3 | 2,795,000a | 3,953,000b | 5,166,000b | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 9.6964a | 9.2274b | 9.4704b |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2024, the total operational greenhouse gas (GHG) emissions of Takeda Pharmaceutical amounted to 545,000 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of Takeda Pharmaceutical decreased by 2.85%, showing that the company has made progress in taking action to reduce the climate impact of its operations.ab
In 2024, the total Scope 1 emissions of Takeda Pharmaceutical were 273,000 metric tons of CO₂ equivalent (tCO₂e).a
Since 2020, Takeda Pharmaceutical's Scope 1 emissions have decreased by 6.83%, reflecting a declining long-term trend in Scope 1 emissions over time.ab
Compared to the previous year (2023), Takeda Pharmaceutical's Scope 1 emissions decreased by 2.15%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.ab
In 2024, Takeda Pharmaceutical reported Scope 2 greenhouse gas (GHG) emissions of 28,000 tCO₂e using the market-based method and 272,000 tCO₂e using the location-based method.a
Since 2020, Takeda Pharmaceutical's Scope 2 greenhouse gas (GHG) emissions (Location-Based) have remained relatively stable, indicating that Takeda Pharmaceutical's emissions have plateaued with no significant change in its energy consumption footprint.ab
Compared to the previous year (2023), Takeda Pharmaceutical's Scope 2 emissions (Location-Based) have remained relatively stable, indicating that Takeda Pharmaceutical's emissions have plateaued with no significant change in its energy consumption footprint.ab
In 2024, Takeda Pharmaceutical reported its Scope 2 emissions using the market-based method and using the location-based method.a
In 2024, Takeda Pharmaceutical reported 2,795,000 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2024 disclosure of Takeda Pharmaceutical includes a breakdown across 10 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2023, demonstrating consistent Scope 3 emissions reporting coverage year over year.a
In 2024, Takeda Pharmaceutical reported total Scope 3 emissions of 2,795,000 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 90.66% of these emissions originated from upstream activities such as purchased goods and capital goods, while 9.34% came from downstream activities like product use, distribution, and end-of-life treatment.a
Since 2020, Takeda Pharmaceutical's Scope 3 emissions have decreased by 36.19%, reflecting a declining long-term trend in Scope 3 emissions over time.ab
Compared to the previous year (2023), Takeda Pharmaceutical's Scope 3 emissions decreased by 29.29%, highlighting the company's efforts to lower indirect emissions from its value chain.ab
In 2024, Takeda Pharmaceutical reported emissions for 10 out of the 15 Scope 3 categories defined by the GHG Protocol.a
This reflects a high level of granularity and transparency in the company's emissions reporting.
In 2024, the largest contributors to Takeda Pharmaceutical's Scope 3 emissions were:a
In 2024, Takeda Pharmaceutical reported Scope 1 greenhouse gas (GHG) emissions of 273,000 tCO₂e and total revenues of USD 28,155 millions. This translates into an emissions intensity of 9.7 tCO₂e per millions USD.a
In 2024, Takeda Pharmaceutical reported a Scope 1 emissions intensity of 9.7 tCO₂e per millions USD. Compared to the peer group median of 7.7, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
In 2024, Takeda Pharmaceutical ranked 15 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
Takeda Pharmaceutical is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a
In 2024, Takeda Pharmaceutical reported a total carbon footprint of 3,340,000 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 26.01% decrease compared to 2023, indicating progress in reducing its overall greenhouse gas output.ab
The largest contributor to Takeda Pharmaceutical's total carbon footprint was Scope 3 emissions, accounting for 83.68% of the company's total carbon footprint, followed by Scope 1 emissions at 8.17%.a